To maintain the efficacy of drugs metabolized by CYP3A4, pan-CYP3A inhibitor is often co-administered, but the high homology between CYP3A4 and CYP3A5 has hampered the development of selective CYP3A4 inhibitors. Here, the authors report a series of selective CYP3A4 inhibitors and show that differential C-terminal loop conformations and two distinct ligand binding surfaces disfavour the binding of selective CYP3A4 inhibitors to CYP3A5.
- Jingheng Wang
- Stanley Nithianantham
- Taosheng Chen